KD Logo

Analyzing Regulus Therapeutics Inc (RGLS) After Recent Trading Activity

Regulus Therapeutics Inc’s filing revealed that its Chief Executive Officer Hagan Joseph P unloaded Company’s shares for reported $17359.0 on Jan 18 ’24. In the deal valued at $1.19 per share,14,580 shares were sold. As a result of this transaction, Hagan Joseph P now holds 57,112 shares worth roughly $0.12 million.

Then, CALSADA CRISPINA sold 5,468 shares, generating $6,510 in total proceeds. Upon selling the shares at $1.19, the Chief Financial Officer now owns 5,782 shares.

Before that, Aker Christopher Ray sold 5,468 shares. Regulus Therapeutics Inc shares valued at $6,510 were divested by the Sr. VP & General Counsel at a price of $1.19 per share. As a result of the transaction, Aker Christopher Ray now holds 10,056 shares, worth roughly $20916.48.

Leerink Partners initiated its Regulus Therapeutics Inc [RGLS] rating to an Outperform in a research note published on March 18, 2024; the price target was $6. A number of analysts have revised their coverage, including B. Riley FBR Inc.’s analysts, who began to cover the stock in late March with a ‘”a Neutral”‘ rating. Leerink Partners began covering RGLS with “an Outperform” recommendation on January 05, 2018. Chardan Capital Markets maintained its rating on June 13, 2017. It rated RGLS as “a Buy”.

Price Performance Review of RGLS

On Tuesday, Regulus Therapeutics Inc [NASDAQ:RGLS] saw its stock fall -0.48% to $2.08. Over the last five days, the stock has lost -6.73%. Regulus Therapeutics Inc shares have risen nearly 62.50% since the year began. Nevertheless, the stocks have risen 19.20% over the past one year. While a 52-week high of $3.79 was reached on 03/12/24, a 52-week low of $1.08 was recorded on 01/17/24. SMA at 50 days reached $2.38, while 200 days put it at $1.63. A total of 0.57 million shares were traded, compared to the trading of 0.54 million shares in the previous session.

Levels Of Support And Resistance For RGLS Stock

The 24-hour chart illustrates a support level at 2.00, which if violated will result in even more drops to 1.93. On the upside, there is a resistance level at 2.16. A further resistance level may holdings at 2.25. The Relative Strength Index (RSI) on the 14-day chart is 40.08, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.22, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.13%. Stochastics %K at 8.38% indicates the stock is a buying.

The most recent change occurred on March 06, 2017 when Wedbush resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $6.

Most Popular

[the_ad id="945"]